^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    xentuzumab (BI-836845)

    i
    Company:
    Boehringer Ingelheim, Novartis
    Drug class:
    IGF-2 inhibitor, IGF1 inhibitor
    Apply
    The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (NCT03659136)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    11/28/2018
    Primary completion :
    08/30/2021
    Completion :
    05/11/2022
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    everolimus • exemestane • xentuzumab (BI-836845)
    This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. (NCT03099174)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    03/05/2024
    Initiation :
    05/04/2017
    Primary completion :
    05/31/2023
    Completion :
    05/30/2024
    HER-2 • ER • ALK • PGR
    |
    EGFR mutation • HER-2 negative • ALK translocation
    |
    Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • xentuzumab (BI-836845)
    BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer (NCT02123823)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/03/2022
    Initiation :
    05/15/2014
    Primary completion :
    11/25/2016
    Completion :
    12/14/2021
    HER-2 • ER • PGR
    |
    everolimus • exemestane • xentuzumab (BI-836845)